Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06305767
Title A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Merck Sharp & Dohme LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | TUR | SWE | POL | NZL | ITA | GBR | FRA | ESP | DEU | CAN | AUS


No variant requirements are available.